1324 Results for "

solution

" in MedChemExpress (MCE) Product Catalog:
Products (1324)

1324 Results for "solution" in MCE Product Catalog:

Cat. No.: HY-P74769Y
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LOXL2; Lysyl Oxidase-Related Protein 2; Lysyl Oxidase Like 2; Lysyl Oxidase-Like 2 Delta E13; Lysyl Oxidase-Like Protein 2; Lysyl Oxidase-Like 2 Protein; Lysyl Oxidase Homolog 2; Lysyl Oxidase Related 2; WS9-14; Lysyl Oxidase Homolog; LOR; Lysyl Oxidase-L
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-L906
646 compounds

On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters.

The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

Cat. No.: HY-L902
4,999 compounds

MCE 5K Scaffold Library consists of 5,000 lead-like compounds. Each compound represents one unique scaffold. All compounds are compatible with Lipinski’s rule (Rule of 5) with multiple characteristics such as calculated good solubility (-3.2 < logP < 5), oral bioavailability (RotB <= 10), drug transportability (PSA < 120). Compounds contained within the library have been screened to remove any inappropriate chemical structures, avoiding “false hits”. The sufficient diverse of compound structure makes this library a powerful tool for drug screening.

Cat. No.: HY-P7890
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CFH; H Factor 1 (Complement); Prev. HF1; Adrenomedullin Binding Protein; Prev. HF2; Beta-1-H-Globulin; Prev. HF; Factor H-Like 1; ARMS1; H Factor 1; ARMD4; Factor H; FHL1; AHUS1; HUS; AMBP1; Age-Related Maculopathy Susceptibility 1; CFHL3; H Factor 2 (Com
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P71189
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PCSK9; PC9; Prev. HCHOLA3; Hypercholesterolemia, Autosomal Dominant 3; NARC-1; Neural Apoptosis Regulated Convertase 1; Subtilisin/Kexin-Like Protease PC9; Neural Apoptosis-Regulated Convertase 1; FH3; LDLCQ1; Proprotein Convertase 9; FHCL3; NARC1; Proprotein Convertase Subtilisin/Kexin Type 9; Convertase Subtilisin/Kexin Type 9 Preproprotein
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P72970
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: DLL1; Delta-Like Ligand 1; Delta Like Canonical Notch Ligand 1; Delta-Like Protein; Drosophila Delta Homolog 1; DELTA1; Delta-Like Protein 1; NEDBAS; H-Delta-1; Delta1; Epididymis Secretory Sperm Binding Protein; Delta; Delta (Drosophila)-Like 1; DL1; Del
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P703882
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CD93; DJ737E23.1; Prev. C1QR1; ECSM3; Prev. MXRA4; Matrix-Remodeling-Associated Protein 4; C1qR(P); Matrix-Remodelling Associated 4; CDw93; C1qR; Complement Component 1 Q Subcomponent Receptor 1; Complement Component 1, Q Subcomponent, Receptor 1; Complem
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P1363S1
β-Amyloid (1-42), human, Ala( 13C3, 15N) TFA is the 13C and 15N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .
loading...
    loading...
Cat. No.: HY-L929
2,527 compounds

In drug discovery and development (R&D) area, target binding and druggability optimization are core processes. Among these attributes, high solubility is critical for a compound to achieve druggability, as it directly impacts the progress of drug R&D. Superior solubility ensures the rapid dissolution and uniform distribution of drug molecules in vivo, thereby enhancing bioavailability and effectively mitigating issues such as suboptimal efficacy, increased dosage requirements, or exacerbated toxic and side effects arising from insufficient solubility.

From the perspective of medicinal chemistry, high-solubility drug fragments serve as high-quality "molecular building blocks". Based on these fragments, lead compounds with potential druggability can be rapidly screened out, which significantly shortens the drug R&D cycle and reduces R&D costs. Meanwhile, the high-solubility drug fragment library can provide diverse options for drug development in different therapeutic areas, offer solutions for the solubility defects of existing clinical drugs, and facilitate the development of novel, highly effective targeted drugs with higher bioavailability and better safety profiles.

MCE has collected and compiled 2,527 experimentally validated small-molecule fragments with high solubility. These fragments can be directly used for drug molecular design, providing high-quality pre-validated solubility fragments that significantly improve the efficiency of lead compound screening and accelerate the progress of drug R&D.

Cat. No.: HY-P76510
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NLGN3; Neuroligin 3 Isoform D; Neuroligin 3; Neuroligin 3 Isoform E; KIAA1480; Neuroligin 3 Isoform C; HNL3; Neuroligin 3 Isoform B; Gliotactin Homolog; Neuroligin 3 Isoform 1; Neuroligin-3; Neuroligin 3 Isoform A; ASPGX1; NLGN3 Protein; AUTSX1; NL3; Neuroligin 3 Isoform 2
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P701153
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NHERF1; Solute Carrier Family 9 Isoform A3 Regulatory Factor 1; Prev. SLC9A3R1; Na(+)/H(+) Exchange Regulatory Cofactor 1; NHERF-1; SLC9A3 Regulator 1; NHERF; Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 3 Regulatory Factor 1; EBP50; Solut
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P701139
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HNF4A; TCF-14; Prev. TCF14; Hepatocyte Nuclear Factor 4 4 Alpha Variant 4; Prev. MODY1; Hepatocyte Nuclear Factor 4 4 Alpha Variant 1; Prev. MODY; Hepatocyte Nuclear Factor 4 4 Alpha Variant 2; NR2A1; Truncated Hepatocyte Nuclear Factor 1 Alpha; HNF4; HNF
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P72946Y
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CFH; H Factor 1 (Complement); Prev. HF1; Adrenomedullin Binding Protein; Prev. HF2; Beta-1-H-Globulin; Prev. HF; Factor H-Like 1; ARMS1; H Factor 1; ARMD4; Factor H; FHL1; AHUS1; HUS; AMBP1; Age-Related Maculopathy Susceptibility 1; CFHL3; H Factor 2 (Com
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-L0121V
10,000 compounds

Natural products are an attractive source with varied structures that exhibit potent biological activities, and desirable pharmacological profiles. The core scaffold of a natural product can also provide a biologically validated framework upon which to display diverse functional groups. Inspired by bioactive natural products, natural product-like compounds, occupying the same chemical space, are ideally suited to explore and to facilitate understanding of biological pathways.

MCE 10K Natural Product-like Compound Library consists of 10,000 natural product-like compounds. Each compound has scaffold of natural products or Tanimoto coefficient >0.6 with natural products. The natural-likeness scoring of these compounds is >-2. What’s more, compounds in the library are drug-like and readily available for re-supply, making it a powerful tool for new drug research and development. It can be widely applied in high-throughput screening (HTS) and high-content screening (HCS).

Cat. No.: HY-L905
4,813 compounds

Natural products are an attractive source with varied structures that exhibit potent biological activities, and desirable pharmacological profiles. The core scaffold of a natural product can also provide a biologically validated framework upon which to display diverse functional groups. Inspired by bioactive natural products, natural product-like compounds, occupying the same chemical space, are ideally suited to explore and to facilitate understanding of biological pathways.

MCE 5K Natural Product-like Compound Library consists of 4,813 natural product-like compounds. Each compound has scaffold of natural products or Tanimoto coefficient >0.6 with natural products. The natural-likeness scoring of these compounds is >-2. What’s more, compounds in the library are drug-like and readily available for re-supply, making it a powerful tool for new drug research and development. It can be widely applied in high-throughput screening (HTS) and high-content screening (HCS).

Cat. No.: HY-P74395Y
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VTCN1; V-Set Domain Containing T Cell Activation Inhibitor 1; B7-H4; B7H4; B7h.5; B7S1; B7x; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Immune Costimulatory Protein B7-H4; B7 Superfamily Member 1; B7 Family Member, H4; B7 Homolog 4; FLJ22418;
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-L901
50,000 compounds

MCE 50K Diversity Library consists of 50,000 lead-like compounds with multiple characteristics such as calculated good solubility (-3.2 < logP < 5), oral bioavailability (RotB <= 10), drug transportability (PSA < 120). These compounds were selected by dissimilarity search with an average Tanimoto Coefficient of 0.52. There are 36,857 unique scaffolds and each scaffold 1 to 7 compounds. What’s more, compounds with the same scaffold have as many functional groups as possible, which make abundant chemical spaces. This exceptionally diverse library is highly recommended for random screening against new as well as popular targets based its novel, diverse scaffolds, abundant chemical spaces and the convenience for subsequent modification.

Cat. No.: HY-D1056A3
Synonyms: LPS, from Escherichia coli (O26:B6)
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
loading...
    loading...
Cat. No.: HY-P73865
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ITGAV; Integrin, Alpha V (Vitronectin Receptor, Alpha Polypeptide, Antigen CD51); Prev. MSK8; Vitronectin Receptor; Prev. VNRA; Integrin AlphaVbeta3; Prev. VTNR; Integrin, Alpha V; Vitronectin Receptor Subunit Alpha; CD51 Antigen; Integrin Alpha-V; IDNDC; CD51; Integrin Subunit Alpha V; Antigen Identified By Monoclonal Antibody L230; ITGB8; Integrin, Beta 8; Integrin Subunit Beta 8; Integrin Beta; Integrin Beta-8
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P702569A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFSF15; TL1A; TNF Superfamily Member 15; Vascular Endothelial Growth Inhibitor-192A; Vascular Endothelial Cell Growth Inhibitor; Vascular Endothelial Growth Inhibitor; TNF Ligand-Related Molecule 1; TNF Superfamily Ligand TL1A; VEGI; MGC129934; TL1; MGC129935; Tumor Necrosis Factor (Ligand) Superfamily, Member 15; Tumor Necrosis Factor Superfamily Member 15; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor Ligand 1B; VEGI192A; TNLG1B
Species:  
Human
Source:  
HEK293
loading...
    loading...